Free Trial

NexGel (NXGL) Competitors

NexGel logo
$2.60 -0.02 (-0.76%)
As of 07/3/2025 01:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NXGL vs. INO, TELA, EDAP, MLSS, MDAI, SURG, HYPR, NEPH, ICCM, and APT

Should you be buying NexGel stock or one of its competitors? The main competitors of NexGel include Inovio Pharmaceuticals (INO), TELA Bio (TELA), Edap Tms (EDAP), Milestone Scientific (MLSS), Spectral AI (MDAI), SurgePays (SURG), Hyperfine (HYPR), Nephros (NEPH), IceCure Medical (ICCM), and Alpha Pro Tech (APT). These companies are all part of the "medical equipment" industry.

NexGel vs. Its Competitors

Inovio Pharmaceuticals (NASDAQ:INO) and NexGel (NASDAQ:NXGL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Inovio Pharmaceuticals currently has a consensus price target of $9.75, suggesting a potential upside of 579.44%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than NexGel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
NexGel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 2.2% of NexGel shares are held by institutional investors. 2.3% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 20.6% of NexGel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Inovio Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

In the previous week, Inovio Pharmaceuticals had 8 more articles in the media than NexGel. MarketBeat recorded 8 mentions for Inovio Pharmaceuticals and 0 mentions for NexGel. Inovio Pharmaceuticals' average media sentiment score of 0.15 beat NexGel's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Inovio Pharmaceuticals Neutral
NexGel Neutral

Inovio Pharmaceuticals has a net margin of 0.00% compared to NexGel's net margin of -30.80%. NexGel's return on equity of -54.95% beat Inovio Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Inovio PharmaceuticalsN/A -136.93% -89.99%
NexGel -30.80%-54.95%-27.84%

NexGel has higher revenue and earnings than Inovio Pharmaceuticals. NexGel is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$220K239.19-$107.25M-$3.19-0.45
NexGel$8.69M2.29-$3.28M-$0.45-5.78

Summary

Inovio Pharmaceuticals beats NexGel on 10 of the 16 factors compared between the two stocks.

Get NexGel News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXGL vs. The Competition

MetricNexGelMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$20.28M$6.95B$5.56B$9.04B
Dividend YieldN/A1.21%5.24%4.01%
P/E Ratio-5.7826.6327.6420.24
Price / Sales2.2998.67416.55117.31
Price / CashN/A21.0936.8958.10
Price / Book2.894.748.035.67
Net Income-$3.28M$173.18M$3.18B$249.21M
7 Day Performance8.33%1.33%2.93%3.28%
1 Month Performance12.55%-1.67%1.72%3.95%
1 Year Performance17.65%25.08%34.39%20.98%

NexGel Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGL
NexGel
0.4069 of 5 stars
$2.60
-0.8%
N/A+17.6%$20.28M$8.69M-5.7810
INO
Inovio Pharmaceuticals
3.8605 of 5 stars
$1.93
-1.5%
$9.75
+405.2%
-83.9%$71.88M$220K-0.61320News Coverage
Gap Down
TELA
TELA Bio
2.5772 of 5 stars
$1.73
+4.8%
$7.25
+319.1%
-52.6%$65.27M$71.22M-1.23120Gap Up
EDAP
Edap Tms
2.3919 of 5 stars
$1.72
+1.3%
$8.50
+394.2%
-69.0%$63.49M$69.18M-2.77230
MLSS
Milestone Scientific
2.8959 of 5 stars
$0.80
-9.1%
$1.25
+56.4%
+1.5%$62.70M$8.61M-11.4130Negative News
Gap Up
MDAI
Spectral AI
2.9885 of 5 stars
$2.05
-6.4%
$4.75
+131.7%
+40.9%$55.44M$29.58M-3.8083News Coverage
Analyst Revision
SURG
SurgePays
3.0518 of 5 stars
$2.73
+1.1%
$9.00
+229.7%
+7.9%$55.11M$60.88M-0.9840
HYPR
Hyperfine
1.8859 of 5 stars
$0.69
0.0%
$1.06
+52.8%
-21.1%$54M$12.89M-1.28190
NEPH
Nephros
0.8576 of 5 stars
$4.29
-14.2%
$5.00
+16.6%
+96.2%$53M$15.52M61.2930News Coverage
Gap Down
High Trading Volume
ICCM
IceCure Medical
2.1056 of 5 stars
$0.92
-3.3%
$2.50
+171.7%
+45.1%$52.79M$3.29M-3.2960News Coverage
APT
Alpha Pro Tech
1.6912 of 5 stars
$4.76
+0.2%
N/A-17.0%$51.60M$58.18M12.86120

Related Companies and Tools


This page (NASDAQ:NXGL) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners